Trial Profile
To evaluate the twice daily oral administration of mogroside, in combination with ribavirin for the treatment of genotype-1, treatment-naive hepatitis-C patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2014
Price :
$35
*
At a glance
- Drugs Mogroside IV (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms Compassionate
- 13 Aug 2014 New trial record
- 01 Jul 2014 Topline results published in a Canopus BioPharma Media Release.